MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  
hematology and blood conditions image

Hematology Drugs

Prescription drugs and medicines for conditions and diseases relating to blood and blood-forming. Studies in this area include: anemia, blood clots, bone marrow transplant, leukemia, platelet disorders, red-cell disorders, T-cell lymphoma, vitamin deficiencies, white-cell disorders, and others.

The list of FDA approved drugs for hematology and blood conditions appears below. Click any link to view the full drug information.


Bookmark and Share
Number Of Hematology Drugs: 90

Actonel
Treatment for Paget's Disease
Adcetris (brentuximab vedotin)
For the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma
Aggrenox
Aggrenox (aspirin/extended-release dipyridamole) 25mg/200mg capules for the prevention of recurrence of stroke
Agrylin (anagrelide HCL)
Treatment for thrombocythemia
AlphaNine SD Coagulation Factor IX (Human)
Treatment for the prevention and control of bleeding in subjects with hemophilia
Argatroban Injection
Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.
Arixtra
Injectable solution for the prevention of deep vein thrombosis
Arzerra (ofatumumab)
For the treatment of chronic lymphocytic leukemia
Atryn (antithrombin recombinant lyophilized powder for reconstitution)
For the prevention of peri-operative and peri-partum thromboembolic events
Beleodaq (belinostat) is a histone deacetylase inhibitor.
For the treatment of relapsed or refractory peripheral T-cell lymphoma
Bexxar
For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse
Bosulif (bosutinib)
For the treatment of Ph+ chronic myelogenous leukemia
Busulflex
For use in combination for the treatment of leukemia
Dacogen (decitabine)
For the treatment of both treatment-naïve and -experienced Myelodysplastic Syndromes
Droxia
Treatment for sickle-cell anemia
Efient (prasugrel)
for the prevention of thrombotic cardiovascular complications in acute coronary syndromes
Elelyso (taliglucerase alfa)
For the treatment of Gaucher disease
Elitek (rasburicase)
For the management of plasma uric acid levels in adults with malignancies
Erwinaze (asparaginase Erwinia chrysanthemi)
For the treatment of acute lymphoblastic leukemia
Femara (letrozole)
Treatment for breast cancer
Feraheme (ferumoxytol)
For the treatment of iron deficiency anemia associated with chronic kidney disease
Ferriprox (deferiprone)
For the treatment of transfusional iron overload due to thalassemia
Ferrlecit
For the treatment of iron deficiency anemia.
Folotyn (pralatrexate injection)
For the treatment of peripheral T-cell lymphoma
Fragmin
Treatment of prophylaxis of deep vein thrombosis (DVT)
Gazyva (obinutuzumab)
For the treatment of previously untreated chronic lymphocytic leukemia
Glucagon
Treatment for severe Hypoglycemia
Glyburide Tablets
Treatment for blood-glucose lowering
Glyburide Tablets
Generic version of Glynase PresTab
Iclusig (ponatinib)
For the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia
Imbruvica (ibrutinib)
For the treatment of chronic lymphocytic leukemia
Imbruvica (ibrutinib)
For the treatment of mantle cell lymphoma
Injectafer (ferric carboxymaltose injection)
For the treatment of iron deficiency anemia
Innohep (tinzaparin sodium) injectable
For the treatment of acute symptomatic deep vein thrombosis
Istodax (romidepsin)
For the treatment of cutaneous T-cell lymphoma
Jakafi (ruxolitinib)
For the treatment of myelofibrosis
Kcentra (Prothrombin Complex Concentrate)
For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency
Kogenate FS (Antihemophilic Factor Recombinant)
For the treatment of hemophilia A
Kuvan (sapropterin dihydrochloride)
For the treatment of hyperphenylalaninemia due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria
Kyprolis (carfilzomib)
For the treatment of multiple myeloma
Leukine (sargramostim)
Treatment for the replenishment of white blood cells
Levitra (vardenafil)
For the treatment of erectile dysfunction related to sexual activity in men
Lovenox (enoxaparin sodium) Injection
Treatment for prevention of blood clots following hip-replacement surgery
Lovenox (enoxaparin sodium) Injection
Treatment for deep vein thrombosis
Lovenox (enoxaparin sodium) Injection
Treatment for acute deep vein thrombosis
Makena (hydroxyprogesterone caproate injection)
For the prevention of risk of preterm birth
Marqibo (vinCRIStine sulfate LIPOSOME injection)
For the treatment of Ph- acute lymphoblastic leukemia
Mircera (methoxy polyethylene glycol-epoetin beta)
For the treatment of anemia associated with chronic renal failure
Mozobil (plerixafor injection)
For the treatment of non-Hodgkin’s lymphoma and multiple myeloma
Nascobal Gel (Cyanocobalamin, USP)
Treatment for vitamin B-12 deficiency
Neulasta
Treatment to decrease the chance of infection by febrile neutropenia in patients receiving chemotherapy
Neumega
Treatment for thrombocytopenia
Neupogen
Treatment for slow white blood cell recovery following chemotherapy
Neutroval (tbo-filgrastim)
For the reduction in the duration of severe chemotherapy-induced neutropenia
Nplate (romiplostim)
For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura
Nymalize (nimodipine)
For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage
Omontys (peginesatide)
For the treatment of anemia due to chronic kidney disease
Pomalyst (pomalidomide)
For the treatment of relapsed and refractory multiple myeloma
Pravachol (pravastatin sodium)
Treatment for cholesterol-lowering
Promacta (eltrombopag)
For the treatment of thrombocytopenia
Ravicti (glycerol phenylbutyrate)
For the treatment of pediatrics and adults with urea cycle disorders
Refludan
Treatment of heparin-induced thrombocytopenia type II
Renagel (sevelamer hydrochloride)
For the control of serum phosphorus in patients with chronic kidney disease on dialysis
Revlimid (lenalidomide)
For the treatment of mantle cell lymphoma
Revlimid (lenalidomide)
For the treatment of low- and intermediate-1-risk myelodysplastic syndromes
Reyataz (atazanavir sulfate)
For the treatment of HIV-1 infection in combination with other antiretroviral agents
Rituxan
Treatment for non-hodgkin's lymphoma
Rixubis (Coagulation Factor IX (Recombinant)]
For the routine prophylaxis and control of hemophilia B
Ruconest (C1 esterase inhibitor [recombinant])
For the treatment of hereditary angioedema
Samsca (tolvaptan)
For the treatment of hyponatremia
Soliris (eculizumab)
For the treatment of atypical hemolytic uremic syndrome
Soliris (eculizumab)
For the treatment of paroxysmal nocturnal hemoglobinuria
Sylvant (siltuximab)
For the treatment of multicentric Castleman’s disease
Synercid I.V.
quinupristin and dalfopristin for injection
Synribo (omacetaxine mepesuccinate)
For the treatment of chronic or accelerated phase chronic myeloid leukemia
Tretten (Coagulation Factor XIII A-Subunit [Recombinant])
For the treatment of congenital factor XIII (FXIII) A-subunit deficiency
Valchlor (mechlorethamine) gel
For the treatment of Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma
Venofer (iron sucrose injection)
For the treatment of iron deficiency anemia in patients undergoing chronic hemodialysis
Vidaza (azacitidine)
For the treatment of several myelodysplastic syndrome subtypes including refractory and chronic myelomonocytic leukemias
Visipaque (iodixanol)
Diagnostic contrast agent
Vpriv (velaglucerase alfa for injection)
For the treatment of type 1 Gaucher disease
Xarelto (rivaroxaban)
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery
Zemaira (alpha1-proteinase inhibitor)
For the treatment of alpha1-proteinase inhibitor deficiency (Alpha-1) and emphysema
Zontivity (vorapaxar)
For the reduction of thrombotic cardiovascular events


« back to top
FDA Approved Hematology Drugs Listings:

The rules of principle for evaluating MediLexicon's FDA hematology drugs listings adhere to the FDA definitions of a new drug approval or a new molecular entity, and the Tufts Center for the Study of Drug Development.

MediLexicon's FDA Approved Drugs Listings include:

New Molecular Entities (NME): these NME's are described as a medication containing an active substance that have never previously approved in the US for marketing in any manner, shape or form (as defined by the FDA). In addition to this, there is also the inclusion of some FDA's Center for Drug Evaluation and Research (CDER) approved recombinant proteins and biologics.

MediLexicon's FDA Approved Drugs Listings do NOT include:

Over-the-counter products, diagnostic agents, generics, most vaccines, medical devices, biologic compounds (not approved by CDER), as well as new indications and new administrations of previously-approved compounds and new dosages.

The hematology drugs information used in this section is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.









MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.